Transcatheter Mitral Valve Replacement: Current Evidence and Concepts.
Ozan M Demir, Mhairi Bolland, Jonathan Curio, Lars Søndergaard, Josep Rodés-Cabau, Simon Redwood, Bernard Prendergast, Antonio Colombo, Mei Chau, Azeem Latib
Author Information
Ozan M Demir: Department of Cardiology, St Thomas' Hospital London, UK.
Mhairi Bolland: Department of Cardiology, Imperial College Healthcare NHS Trust London, UK.
Jonathan Curio: Department of Cardiology, Charité University Medical Care, Campus Benjamin Franklin Berlin, Germany.
Lars Søndergaard: Department of Cardiology, Rigshospitalet, Copenhagen University Hospital Copenhagen, Denmark.
Josep Rodés-Cabau: Quebec Heart and Lung Institute, Laval University Quebec City, Canada.
Simon Redwood: Department of Cardiology, St Thomas' Hospital London, UK.
Bernard Prendergast: Department of Cardiology, St Thomas' Hospital London, UK.
Antonio Colombo: Interventional Cardiology Unit, GVM Care and Research, Maria Cecilia Hospital Cotignola, Italy.
Mei Chau: Department of Cardiac Surgery, Montefiore Medical Center New York, US.
Azeem Latib: Department of Cardiology, Montefiore Medical Center New York, US.
Over the past decade, several transcatheter devices have been developed to address the treatment of severe mitral regurgitation (MR) in patients at high surgical risk, mainly aimed at repairing the native mitral valve (MV). MV repair devices have recently been shown to have high efficacy and safety. However, to replicate promising trial results, specific anatomical and pathophysiological criteria have to be met and operators need a high level of experience. As yet, the longer-term durability of transcatheter MV repair remains unknown. Transcatheter MV replacement (TMVR) might be a treatment option able to target various anatomies, reliably abolish MR, and foster ease of use with a standardised implantation protocol. This review presents upcoming TMVR devices and available data and discusses how TMVR might further advance the field of transcatheter treatment of MR.
